ADJUVANT ANTI-HER2 THERAPY FOR BREAST CANCER


Cite item

Full Text

Abstract

Three European clinical trials (HERA, BCIRG 006, FinHER) and two American clinical trials (NSABP B-31 and NCCTG № 9831), including more over 11 thousand women with HER2-positive breast cancer (BC) with metastases to the lymph nodes show Three European clinical trials (HERA, BCIRG 006, FinHER) and two American clinical trials (NSABP B-31 and NCCTG № 9831), including more over 11 thousand women with HER2-positive breast cancer (BC) with metastases to the lymph nodes show that anti-HER2 target therapy (trastuzumab) in addition to adjuvant chemotherapy leads to increase of recurrence free survival rates by 30 to 40%. Approximately 10% of tumors 1 cm and less in diameter also have expressed HER2, and their prognosis is significantly worse than in patients with HER2-negative tumors at the same stage (pT1a-bN0M). Due to the lack of special clinical trials, significance of anti-HER2 therapy in patients with minimal breast cancer remains unclear.

References

  1. Семиглазов В.Ф. Основные результаты клинических исследований в онкологии в 2009 г. // Фарматека 2010. № 6 (200). C. 16-20.
  2. Spector NL, Blackwell KL. Understanding the mechanisms behind trastu-umab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838-47.
  3. Sjogren S, Inganas M, Lindgren A, et al: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, atone and in combination with other prognostc markers. J Clin Oncol 1998;16:462-69.
  4. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
  5. Ferlay J, Autier P, Boraol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
  6. Makino K, Dav CP, Wang SC, et al. upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required HER2/neu-induced NF-kappaB antiapoptotic pathway Oncogene 2004;23:3883-87.
  7. Bacus SS, Altomare DA, Lyass L, et al. AKT2 is frequently upregutated n HER-2/neu-positive breast cancers and may contnbute to tumor aggressiveness by enchancing cell survival. Oncogene 2002;21:3532-40.
  8. Xia W, Bisi J, Strum J, et al. Regulation of survivin by ErbB2 signaling: Theurapeutic implications for ErbB2-overexpressing breast cancer. Cancer Res 2006;66:1640-47.
  9. Yakes FM, Chinratanalab W, Ritter CA, et al. A Herceptin-induced inhibition of phosphatidilinozitol-3-kinase and Akt is required for antibody-mediated effects on p27, Cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
  10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  11. Perez EA, Romond EH, Suman V, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 18:255-56.
  12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
  13. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
  14. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable IIER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  15. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol (Meeting Abstracts) 2007;25:6-7.
  16. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim analysis. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 7-10 December 2005 (oral presentation).
  17. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 9-13 December 2009 (oral presentation).
  18. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 9-13 December 2009 (abstract 80).
  19. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial. J Clin Oncol 2007;25:3859-65.
  20. Hanrahan EO, Valero V, Gonzalez-Angulo AM, et al: Prognosis and man-icement of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1abN0M0): A review of the literature. J Clin Oncol 2006;24:2113-22.
  21. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1 N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 2003;9:923-30.
  22. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both: Prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002;20:4141-49.
  23. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue. J Clin Oncol 2008;26:5697-704.
  24. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693-99
  25. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700-06
  26. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Treatment of node-negative infra-centimeric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol 2009;27:10.
  27. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial. J Clin Oncol 2009;27:5685-92.
  28. Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol 2005;23:17.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies